1.76
0.02 (1.15%)
| Penutupan Terdahulu | 1.74 |
| Buka | 1.69 |
| Jumlah Dagangan | 344,321 |
| Purata Dagangan (3B) | 316,949 |
| Modal Pasaran | 129,595,136 |
| Harga / Pendapatan (P/E Ke hadapan) | 2.83 |
| Harga / Jualan (P/S) | 2.99 |
| Harga / Buku (P/B) | 4.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Mar 2025 - 17 Mar 2025 |
| Margin Keuntungan | -38.62% |
| Margin Operasi (TTM) | -18.01% |
| EPS Cair (TTM) | -0.150 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -61.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 91.50% |
| Nisbah Semasa (MRQ) | 1.34 |
| Aliran Tunai Operasi (OCF TTM) | -2.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.32 M |
| Pulangan Atas Aset (ROA TTM) | -10.27% |
| Pulangan Atas Ekuiti (ROE TTM) | -43.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Protalix BioTherapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 14.53% |
| % Dimiliki oleh Institusi | 5.20% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Stratos Wealth Partners, Ltd. | 30 Sep 2024 | 270,000 |
| Orin Green Financial, Llc | 30 Sep 2024 | 72,000 |
| Point72 Asia (Singapore) Pte. Ltd. | 30 Sep 2024 | 47,073 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 Dec 2024 | Pengumuman | Protalix BioTherapeutics Issues 2025 Letter to Stockholders |
| 09 Dec 2024 | Pengumuman | Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa |
| 14 Nov 2024 | Pengumuman | Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results |
| 07 Nov 2024 | Pengumuman | Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 |
| 25 Oct 2024 | Pengumuman | Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |